SEC Tracker
Get the app

Recursion Pharmaceuticals RXRX

Blake Borgeson (Director) sold 40,000 RXRX at $3.88, worth $155K, under a 10b5-1 plan

Form
4
Filed
Importance
Routine
  1. Sold 40,000 Class A Common Stock
  2. Price range $3.84 to $4.00
  3. Executed under a pre-planned trading plan

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Recursion Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Bausch Health Companies BHC public float $2.0B, Jun 30, 2025
  2. Vericel VCEL public float $2.1B, Jun 30, 2025
  3. Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
  4. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  5. Indivior Pharmaceuticals INDV public float $1.8B, Jun 30, 2025